The Antidepressant-Sensitive Dopamine Transporter inDrosophila melanogaster: A Primordial Carrier for Catecholamines

Abstract

Extracellular concentrations of monoamine neurotransmitters are regulated by a family of high-affinity transporters that are the molecular targets for such psychoactive drugs as cocaine, amphetamines, and therapeutic antidepressants. In Drosophila melanogaster, cocaine-induced behaviors show striking similarities to those induced in vertebrate animal models. Although a cocaine-sensitive serotonin carrier exists in flies, there has been no pharmacological or molecular evidence to support the presence of distinct carrier subtypes for other bioactive monoamines. Here we report the cloning and characterization of a cocaine-sensitive fly dopamine transporter (dDAT). In situ hybridization demonstrates that dDAT mRNA expression is restricted to dopaminergic cells in the fly nervous system. The substrate selectivity of dDAT parallels that of the mammalian DATs in that dopamine and tyramine are the preferred substrates, whereas octopamine is transported less efficiently, and serotonin not at all. In contrast, dDAT inhibitors display a rank order of potency most closely resembling that of mammalian norepinephrine transporters. Cocaine has a moderately high affinity to the cloned dDAT (IC50 = 2.6 μM). Voltage-clamp analysis of dDAT expressed in Xenopus laevis oocytes indicates that dDAT-mediated uptake is electrogenic; however, dDAT seems to lack the constitutive leak conductance that is characteristic of the mammalian catecholamine transporters. The combination of a DAT-like substrate selectivity and norepinephrine transporter-like inhibitor pharmacology within a single carrier, and results from phylogenetic analyses, suggest that dDAT represents an ancestral catecholamine transporter gene. The identification of a cocaine-sensitive target linked to dopaminergic neurotransmission in D. melanogaster will serve as a basis for further dissection of the genetic components of psychostimulant-mediated behavior.

Footnotes

  • Send reprint requests to: Peter Pörzgen or Susan G. Amara, 3181 SW Sam Jackson Park Rd., OHSU, Vollum Institute L-474, Portland, OR, 97201. Email: poerzgen{at}ohsu.edu;amaras{at}ohsu.edu

  • This work was supported by Grants from NARSAD (M.S.S.), the National Institute on Drug Abuse (DA07595 and DA12408) (S.G.A.), National Institutes of Health Grant GM/DA27318 (J.H.), and the Deutsche Forschungsgemeinschaft (P.P.).

  • Parts of this work were presented at the 29th Annual Meeting of the Society for Neuroscience (Soc Neurosci1999;25:160).

  • Abbreviations:
    DA
    dopamine
    NE
    (−)-norepinephrine
    5-HT
    5-hydroxytryptamine (serotonin)
    DAT
    dopamine transporter
    SERT
    serotonin transporter
    NET
    norepinephrine transporter
    TA
    p-tyramine
    dSERT
    Drosophila melanogaster serotonin transporter
    OA
    octopamine
    TMD
    transmembrane domain
    ceDAT
    Caenorhabditiselegans dopamine transporter
    dDAT
    Drosophila melanogaster dopamine transporter
    NTT
    neurotransmitter transporter
    hDAT
    human dopamine transporter
    bp
    base pair(s)
    kb
    kilobase pair(s)
    EST
    expressed sequence tag
    RT
    reverse transcriptase
    PCR
    polymerase chain reaction
    COS-7
    SV40-transformed African green monkey kidney cells
    MDCK
    Madin-Darby canine kidney
    KRH
    Krebs-Ringer's-HEPES
    hSERT
    human serotonin transporter
    hNET
    human norepinephrine transporter
    EL
    extracellular loop
    PK-C
    protein kinase C
    AA
    amino acid
    CNS
    central nervous system
    Epi
    (−)-epinephrine
    fET
    frog epinephrine transporter
    TCA
    tricyclic antidepressant
    • Received August 16, 2000.
    • Accepted October 10, 2000.
« Previous | Next Article »Table of Contents